BioCryst to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
BioCryst Pharma (BCRX) PT Raised to $18 at Cowen
May 6, 2021 10:19 AM EDTCowen analyst Ken Cacciatore raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $18.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "BioCryst reported strong first full quarter Orladeyo sales, and we view the initial launch metrics of meaningful patient switches (vs. clinical trial... More



